The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...
Biosimilars revolutionize health care access in Latin America, offering cost savings and improved treatment availability for ...
A new study confirms that biosimilar ranibizumab matches innovator Lucentis in treating myopic choroidal neovascular membrane ...
Researchers report that biosimilar use was not influenced by disease type but correlated with treatment sequence, shorter ...
Omalizumab biosimilars promise significant savings for European health systems, enhancing access to vital therapies for patients with severe allergies. Biosimilars have been touted for years as a way ...
AVT06, a promising biosimilar to aflibercept (Eylea), shows comparable efficacy and safety for treating neovascular age-related macular degeneration (AMD), enhancing patient access. AVT06, a proposed ...
The latest advancements in global biosimilar access include new treatments, strategic partnerships, and competitive market entries enhancing patient care. The global biosimilar industry experienced ...
Biosimilar approvals surge in the US and Europe, enhancing access to denosumab and aflibercept therapies while driving significant health care savings. In September 2025, biosimilars continued to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback